학술논문
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Document Type
Article
Author
Ruckwardt, Tracy J; Morabito, Kaitlyn M; Phung, Emily; Crank, Michelle C; Costner, Pamela J; Holman, LaSonji A; Chang, Lauren A; Hickman, Somia P; Berkowitz, Nina M; Gordon, Ingelise J; Yamshchikov, Galina V; Gaudinski, Martin R; Lin, Bob; Bailer, Robert; Chen, Man; Ortega-Villa, Ana M; Nguyen, Thuy; Kumar, Azad; Schwartz, Richard M; Kueltzo, Lisa A; Stein, Judith A; Carlton, Kevin; Gall, Jason G; Nason, Martha C; Mascola, John R; Chen, Grace; Graham, Barney S; Arthur, Anita; Cunningham, Jennifer; Eshun, Aba; Larkin, Brenda; Mendoza, Floreliz; Novik, Laura; Saunders, Jamie; Wang, Xiaolin; Whalen, William; Carter, Cristina; Hendel, Cynthia Starr; Plummer, Sarah; Ola, Abidemi; Widge, Alicia; Burgos Florez, Maria C; Le, Lam; Pittman, Iris; Rothwell, Ro Shauna S; Trofymenko, Olga; Vasilenko, Olga; Apte, Preeti; Hicks, Renunda; Cartagena, Cora Trelles; Williams, Pernell; Requilman, LaShawn; Tran, Colin; Bai, Shufeng; Carey, Elizabeth; Chamberlain, Amy L; Chang, Ya-chen; Chen, Mingzhong; Chen, Peifeng; Cooper, Jon; Fridley, Colleen; Ghosh, Mridul; Gollapudi, Deepika; Holland-Linn, Janel; Horwitz, Joe; Hussain, Althaf; Ivleva, Vera; Kaltovich, Florence; Leach, Kristin; Lee, Christopher; Liu, Amy; Liu, Xun; Manceva, Slobodanka; Menon, Amritha; Nagy, Attila; O'Connell, Sarah; Ragunathan, Rahul; Walters, Jennifer; Zhao, Zhong
Source
The Lancet Respiratory Medicine; October 2021, Vol. 9 Issue: 10 p1111-1120, 10p
Subject
Language
ISSN
22132600; 22132619
Abstract
Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sustainable boost in neutralising activity is required to protect against severe RSV disease. To that end, we evaluated the safety and immunogenicity of DS-Cav1, a prefusion F subunit vaccine.